Publications

Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C. (2014) Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biol. 12(7):e1001906.

Backen A, Renehan A, Clamp A, Berzuini C, Zhou C, Oza AM, Bannoo S, Scherer SJ, Banks RE, Dive C, Jayson GC. (2014) The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients. Clin Cancer Res. 2014 Jun 19. pii: clincanres.3248.2013. [Epub ahead of print]

Morris KL, Tugwood JD, Khoja L, Lancashire M, Sloane R, Burt D, Shenjere P, Zhou C, Hodgson C, Ohtomo T, Katoh A, Ishiguro T, Valle JW, Dive C. (2014) Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2014 Jun 13. [Epub ahead of print]

Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A. Circulating tumor cells as tumor biomarkers in melanoma: detection methods and clinical relevance. (2014) Ann Oncol. 2014 Jun 6. pii: mdu207. [Epub ahead of print] Review.

Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C. (2014) Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 20(8):897-903.

Greystoke A, Harris G, Jenkins M, Goonetilleke D, Moore D, Lancashire M, Ranson M, Hughes A, Clack G, Dive C. Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication. J Pharm Biomed Anal. 2013 84:184-8.

Linnik IV, Scott ML, Holliday KF, Woodhouse N, Waterton JC, B O'Connor JP, Barjat H, Liess C, Ulloa J, Young H, Dive C, Hodgkinson CL, Ward T, Roberts D, Mills SJ, Thompson G, Buonaccorsi GA, Cheung S, Jackson A, Naish JH, Parker GJ. (2014) Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma. Magn Reson Med. 71(5):1854-62.

Honeychurch J, Dive C, Illidge TM. Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. Oncoimmunology. 2013 2(6):e24501.

Adamski J, Price A, Dive C, Makin G. Hypoxia-Induced Cytotoxic Drug Resistance in Osteosarcoma Is Independent of HIF-1Alpha. PLoS One. 2013 8(6):e65304.

Simpson KL, Cawthorne C, Zhou C, Hodgkinson CL, Walker MJ, Trapani F, Kadirvel M, Brown G, Dawson MJ, MacFarlane M, Williams KJ, Whetton AD, Dive C. A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers. Cell Death Dis. 2013 May 2;4:e613. doi: 10.1038/cddis.2013.137.

Cawthorne C, Burrows N, Gieling RG, Morrow CJ, Forster D, Gregory J, Radigois M, Smigova A, Babur M, Simpson K, Hodgkinson C, Brown G, McMahon A, Dive C, Hiscock D, Wilson I, Williams KJ.  [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941. Mol Cancer Ther. 2013 12(5):819-28.

Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol. 2013 133(6):1582-90.

Vaughan AA, Dunn WB, Allwood JW, Wedge DC, Blackhall FH, Whetton AD, Dive C, Goodacre R. Liquid chromatography-mass spectrometry calibration transfer and metabolomics data fusion. Anal Chem. 2012 84(22):9848-57.

Carter L, Metcalf R, Blackhall FH, Dive C, Krebs MG. Biology and clinical relevance of circulating tumour cells. J Thorac Dis. 2012 4(5):453-5.

Mustafi R, Dougherty U, Shah H, Dehghan H, Gliksberg A, Wu J, Zhu H, Joseph L, Hart J, Dive C, Fichera A, Threadgill D, Bissonnette M. Both stromal cell and colonocyte epidermal growth factor receptors control HCT116 colon cancer cell growth in tumor xenografts. Carcinogenesis. 2012 33(10):1930-9.

Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 18(11):3163-9.

Dean E, Greystoke A, Ranson M, Dive C. Biomarkers of cell death applicable to early clinical trials. Exp Cell Res. 2012 318(11):1252-9.

Zhou C, Simpson KL, Lancashire LJ, Walker MJ, Dawson MJ, Unwin RD, Rembielak A, Price P, West C, Dive C, Whetton AD. Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. J Proteome Res. 2012 11(4):2103-13.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012 30(5):525-32.

Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, Dive C. A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients. Clin Drug Investig. 2012 32(3):179-87.

Stovold R, Blackhall F, Meredith S, Hou J, Dive C, White A. Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer. 2012 76(3):263-8.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012 7(2):306-15.

Cummings, J., Zweifel, M., Smith, N., Ross, P., Peters, J., Rustin, G., Price, P., Middleton, M.R., Ward, T., and Dive, C. (2012) Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br J Cancer 106, 1766-1771.

Greystoke, A., Dean, E., Saunders, M.P., Cummings, J., Hughes, A., Ranson, M., Dive, C., and Renehan, A.G. (2012) Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. Br J Cancer 107, 1518-1524.

Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., Board, R., Clack, G., Hughes, A., Blackhall, F., Valle, J.W., and Dive, C. (2012) A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer 106, 508-516.

Klymenko T, Brandenburg M, Morrow C, Dive C, Makin G. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol Cancer Ther. 2011 10(12):2373-83.

Hitchman E, Hodgkinson C, Roberts D, Ashton G, Yunus Z, Byers R, Ward T, Womack C, Dive C. Effect of prolonged formalin fixation on immunohistochemical staining for the proliferation marker Ki67. Histopathology. 2011 59(6):1261-3.

Current Status and Future Potential of Somatic Mutation Testing from Circulating Free DNA in Patients with Solid Tumours. Aung K, Board R, Ellison G, Donald E, Ward T, Clack G, Ranson M, Hughes A, Newman W, Dive C. The HUGO J (In press)

Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer. Dean EJ, Cummings J, Roulston A, Berger M, Ranson M, Blackhall F, Dive C. Neoplasia. 2011 (4):339-47.

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM, Radford J, Dive C. Br J Cancer, 104:719-25 (2011).

Increased Sensitivity of Human Lung and Colorectal Cancer Cells to the BH-Mimetic ABT-737 in Hypoxia via Down Regulation of Mcl-1. Harrison L, Micha D, Brandenburg M, Morrow C, Simpson K, Makin G, Denenny O, Hodgkinson C, Blackhall F, Dive C Journal of Clinical Investigation, 121(3):1075-87 (2011)

Prognostic Significance and Molecular Characteristics of Circulating Tumour Cells and Circulating Tumour Microemboli in Patients with Small Cell Lung Cancer. Hou JM, Krebs M, Lancashire L, Sloane R, Backen A, Priest L, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH and Dive C. J Clin Oncol, (12):1556-63 (2011).

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall FH and Dive C. Am J Path, i178:989-996 (2011).

Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. Hampson G, Ward TH, Cummings J, Bayne M, Tutt AL, Cragg MS, Dive C, Illidge TM. J Immunol Methods. 31;360(1-2):30-8 (2010)

Src family kinase inhibitor saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. Morrow, C.J., Ghattas, M., Smith, C., Bönisch, H., Bryce, R.A., Hickinson, D.M., Green, T.P., Dive, C. Cancer Research. 70(14):5931-41 (2010)

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Breast Cancer Res Treat. 120(2):461-7 (2010)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A. Br J Cancer. 101(10):1724-30 (2009)

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Williamson A, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, C Dive, Blackhall FH. American Journal of Pathology. 175(2):808-16 (2009)

Blocking PI3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but does not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs. Martin-Fernandez C., Bales J., Hodgkinson C., Welman A., Welham M. J., Dive C. and Morrow C. J. Molecular Cancer Research 7(6):955-65 (2009)

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M. J Clin Oncol. 27(10):1660-6. (2009)

Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C. J Immunol Methods. 342(1-2):106-14. (2009)

Quantitative multiplexed quantum dot immunohistochemistry Sweeney, E.,Ward, T. H.,Gray, N.,Womack, C.,Jayson, G.,Hughes, A., Dive, C.,Byers, R. Biochem Biophys Res Commun 374(2): 181-6. (2008)

Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer Micha, D.,Cummings, J.,Shoemaker, A.,Elmore, S.,Foster, K.,Greaves, M.,Ward, T.,Rosenberg, S.,Dive, C.,Simpson, K. Clin Cancer Res 14(22): 7304-10. (2008).

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Cummings, J.,Hodgkinson, C.,Odedra, R.,Sini, P.,Heaton, S. P.,Mundt, K. E.,Ward, T.,Wilkinson, R. W.,Growcott, J.,Hughes, A.,Dive, C. Mol Cancer Ther 7(3): 455-63. (2008).

Multiplexed assays for detection of mutations in PIK3CA. Board, R. E.,Thelwell, N. J.,Ravetto, P. F.,Little, S.,Ranson, M.,Dive, C.,Hughes, A.,Whitcombe, D. Clin Chem 54(4): 757-60. (2008).

Optimisation of circulating biomarkers of cell death for routine clinical use. Greystoke, A.,Cummings, J.,Ward, T.,Simpson, K.,Renehan, A.,Butt, F.,Moore, D.,Gietema, J.,Blackhall, F.,Ranson, M.,Hughes, A., Dive, C. Ann Oncol 19(5): 990-5. (2008).